-

01:59:00 AM

Latest GBLX Stock Market News

GBLX - GB Sciences Inc

09/14/21 7:00 AM

OTC : GBLX

covid-19

Gb Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related Hyperinflammation

Based on a recently completed preclinical study performed at Michigan State University, Gb Sciences' preclinical data supports further development of their novel cannabinoid-containing complex mixtures as anti-inflammatory therapies for hyperinflammatory conditions associated with COVID-19 and

RHEA-AI

neutral

09/09/21 9:54 AM

OTC : GBLX

covid-19

Gb Sciences Presenting COVID-Related Cytokine Release Syndrome Results at H.C. Wainwright's 23rd Annual Global Investment Conference

Gb Sciences, Inc. (OTCQB:GBLX), a

RHEA-AI

neutral

08/10/21 9:00 AM

OTC : GBLX

conferences

Gb Sciences to Present at the SNN Network Summer Virtual Event on Wednesday, August 18th, 2021

Gb Sciences (OTCQB:GBLX), a plant-based research and biopharmaceutical drug development company, today announced that it will be presenting at the SNN Network Summer Virtual Event 2021 on Wednesday, August 18 th at 3:00 PM EST. Dr. Andrea Small-Howard,

RHEA-AI

neutral

07/27/21 10:10 AM

OTC : GBLX

GB Sciences Is Developing Plant-Inspired Mixtures for Anxiety, Depression, and Pain From PhAROS, GB Sciences' Proprietary AI-Accelerated Drug Discovery Platform

GB Sciences used PhAROS™, their novel AI-accelerated drug discovery platform, to identify and pre-validate optimized therapeutic mixtures for the treatment of anxiety, depression, and pain from mixtures of compounds identified within Kava and other plants from within the Piper family. LAS VEGAS, NV

RHEA-AI

neutral

06/29/21 7:00 AM

OTC : GBLX

GB Sciences Using AI Technology in Plant-Based Drug Discovery Research

GB Sciences (OTCQB:GBLX) is leading the way in cutting-edge

RHEA-AI

neutral

06/17/21 11:20 AM

OTC : GBLX

management

GB Sciences' Board of Directors Has Passed a Unanimous Written Consent Promoting Dr. Andrea Small-Howard to the Role of President

Dr. Andrea Small-Howard has been promoted to the role of President of GB Sciences, Inc. Dr. Small-Howard will also retain her roles as Chief Science Officer and member of the board

RHEA-AI

very positive

04/20/21 7:00 AM

OTC : GBLX

GB Sciences and Purisys Announce Preferred Supplier Relationship to Advance Cannabinoid-Containing Pharmaceuticals

GB Sciences, Inc. (OTCQB:GBLX) and Purisys, LLC, the global industry leader in ultra-high purity, pharmaceutical

RHEA-AI

very positive

04/07/21 7:00 AM

OTC : GBLX

GB Sciences Files Provisional Patent Application to Protect Its Proprietary Drug Discovery Platform

GBS' newest proprietary drug discovery platform uses data analytics and machine learning to gain valuable predictive insights into the likely efficacy of novel plant-derived therapeutics. This unique ability allows researchers to reduce the time and money required for novel, plant-based combination

RHEA-AI

neutral

03/23/21 7:00 AM

OTC : GBLX

GB Sciences Publishes Study on Creation of Novel Terpene-Containing Nanoparticles for Pain Relief

GB Sciences, Inc. (OTCQB:GBLX) and its Spanish research partners at the Universidad de Sevilla (USE) are pleased to announce the publication of a new scientific paper describing the creation of terpene-containing nanoparticles for use in the treatment

RHEA-AI

neutral

10/06/20 9:00 AM

OTC : GBLX

GB Sciences Files Provisional Patent Application for the Treatment of Chronic Inflammation Utilizing Its Novel Cannabinoid Containing Complex Mixtures (CCCM)

GB Sciences, Inc. (OTCQB:GBLX), has filed a provisional patent application, assigned to GBS Global Biopharma (GBS), Inc., for the use of its new proprietary cannabinoid containing complex mixtures (CCCM™) for the treatment of chronic inflammation.

RHEA-AI

neutral